Biomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patients

Laza-Briviesca, R.Cruz-Bermudez, A.Casarrubios, M.Nadal, E.Insa, A.Garcia Campelo, R.De Dios Alvarez, N.Domine, M.Majem, M.Rodriguez-Abreu, D.Calvo De Juan, V.Martinez-Marti, A.De Castro Carpeno, J.Cobo, M.Lopez-Vivanco, G.Del Barco, E.Bernabe, R.Vinolas, N.Barneto, I.Viteri, S.Massuti, B.Provencio, M.2025-01-072025-01-072019-10-011556-0864https://hdl.handle.net/10668/25728enstage IIIA NSCLCbiomarkersneo-adjuvant chemo-immunotherapyBiomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patientsconference outputopen access10.1016/j.jtho.2019.08.15151556-1380http://www.jto.org/article/S1556086419321987/pdf492162203430